Risk factors for complicated community-acquired pneumonia course in patients treated with β-lactam monotherapy

Adv Respir Med. 2021;89(4):359-368. doi: 10.5603/ARM.a2021.0070. Epub 2021 Jul 16.

Abstract

Introduction: We aimed to investigate community-acquired pneumonia (CAP) requiring hospitalisation, empirically treated with b-lactam monotherapy, with 30-day mortality and risk factors predicting its complicated course.

Material and methods: A prospective observational study was conducted at the Pulmonology and Allergology Department in a tertiary care university hospital. 253 consecutive patients diagnosed with CAP requiring hospitalisation were enrolled. Hospital admission was based on PSI or CRB-65 scores, severe comorbidities, signs of intoxication, aspiration risk, social risk consider-ations, ineffective prior antibiotic treatment.

Results: Fourty seven percent of the subjects had complications on admission, 13% developed new CAP complications during inpatient treatment. Overall, 53% of individuals had a complicated CAP course. 30-day mortality rate was 5.9%. The factors predicting a complicated CAP course were as follows: neuromuscular disease, multilobar opacities on chest X-ray (or computed tomography), and clinically unstable condition as evaluated using Halm's criteria.

Conclusions: The mortality rate in CAP patients treated with b-lactam monotherapy is low. Neuromuscular disease, multilobar opacities, and clinically unstable condition as evaluated using Halm's criteria predict a complicated CAP course.

Keywords: community-acquired pneumonia; complications.; mortality; β-lactam monotherapy.

Publication types

  • Observational Study

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / mortality
  • Female
  • Humans
  • Male
  • Pneumonia, Bacterial / drug therapy*
  • Prospective Studies
  • Severity of Illness Index*
  • Treatment Outcome
  • beta-Lactams / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • beta-Lactams